Anjana Bose

1.9k total citations
28 papers, 1.5k citations indexed

About

Anjana Bose is a scholar working on Pharmacology, Experimental and Cognitive Psychology and Psychiatry and Mental health. According to data from OpenAlex, Anjana Bose has authored 28 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pharmacology, 14 papers in Experimental and Cognitive Psychology and 13 papers in Psychiatry and Mental health. Recurrent topics in Anjana Bose's work include Treatment of Major Depression (19 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (12 papers) and Mental Health Research Topics (9 papers). Anjana Bose is often cited by papers focused on Treatment of Major Depression (19 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (12 papers) and Mental Health Research Topics (9 papers). Anjana Bose collaborates with scholars based in United States, India and Cyprus. Anjana Bose's co-authors include W. J. Burke, I. Gergel, Hongjie Zheng, Carl Gommoll, Dayong Li, Chetan C. Gandhi, Andrew Korotzer, Jonathan Davidson, Qin Wang and Mark Hyman Rapaport and has published in prestigious journals such as Journal of Affective Disorders, Schizophrenia Research and The Journal of Clinical Psychiatry.

In The Last Decade

Anjana Bose

27 papers receiving 1.4k citations

Peers

Countries citing papers authored by Anjana Bose

Since Specialization

Citations

This map shows the geographic impact of Anjana Bose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anjana Bose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anjana Bose more than expected).

Fields of papers citing papers by Anjana Bose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anjana Bose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anjana Bose. The network helps show where Anjana Bose may publish in the future.

Co-authorship network of co-authors of Anjana Bose

This figure shows the co-authorship network connecting the top 25 collaborators of Anjana Bose. A scholar is included among the top collaborators of Anjana Bose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anjana Bose. Anjana Bose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Regulatory initiatives for artificial intelligence applications: Regulatory writing implications 2023 ·Medical Writing ·Anjana Bose	0
2	Role of systemic inflammatory markers (biomarkers) as important prognostic factors for survival in head and neck cancer 2021 ·Biomedicine ·(unknown), Dharmendra Singh, Anjana Bose, Siddhartha Das, (unknown), (unknown)	3
3	Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation 2017 ·Schizophrenia Research ·Steven G. Potkin, Robert Risinger, Yangchun Du, Jacqueline Zummo, Anjana Bose, Bernard L. Silverman, Srdjan Stankovic, Elliot Ehrich	12
4	Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia 2016 ·The Journal of Clinical Psychiatry ·Henry A. Nasrallah, John W. Newcomer, Robert Risinger, Yangchun Du, Jacqueline Zummo, Anjana Bose, Srdjan Stankovic, Bernard L. Silverman, Elliot Ehrich	29
5	A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia 2015 ·The Journal of Clinical Psychiatry ·Herbert Y. Meltzer, Robert Risinger, Henry A. Nasrallah, Yangchun Du, Jacqueline Zummo, Lisa M. Corey, Anjana Bose, Srdjan Stankovic, Bernard L. Silverman, Elliot Ehrich	100
6	Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia 2015 ·International Clinical Psychopharmacology ·Leslie Citrome, Yangchun Du, Robert Risinger, Srdjan Stankovic, Amy Claxton, Jacqueline Zummo, Anjana Bose, Bernard L. Silverman, Elliot Ehrich	17
7	Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study 2014 ·Journal of Psychiatry and Neuroscience ·David Bakish, Anjana Bose, Carl Gommoll, Changzheng Chen, René Núñez, William M. Greenberg, Michael R. Liebowitz, Arif Khan	56
8	Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder 2013 ·The Journal of Clinical Psychiatry ·Stuart Montgomery, (unknown), Adam Ruth, Anjana Bose, Hua Li, Dayong Li	61
9	Escitalopram in the Treatment of Adolescent Depression: A Randomized, Double-Blind, Placebo-Controlled Extension Trial 2013 ·Journal of Child and Adolescent Psychopharmacology ·Robert L. Findling, Adelaide S. Robb, Anjana Bose	40
10	Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder 2013 ·The Journal of Clinical Psychiatry ·Gregory M. Asnis, Anjana Bose, Carl Gommoll, Changzheng Chen, William M. Greenberg	70
11	Early Non-Response in Patients with Severe Depression 2012 ·Clinical Drug Investigation ·Anjana Bose, Joyce Tsai, (unknown)	18
12	Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder 2007 ·Depression and Anxiety ·Anjana Bose, Andrew Korotzer, Carl Gommoll, Dayong Li	40
13	Double-Blind Comparison of Escitalopram and Duloxetine in??the??Acute Treatment of Major??Depressive Disorder 2007 ·Clinical Drug Investigation ·Arif Khan, Anjana Bose, George S. Alexopoulos, Carl Gommoll, Dayong Li, Chetan C. Gandhi	72
14	Safety and Efficacy of Escitalopram in the Long-Term Treatment of Generalized Anxiety Disorder 2005 ·The Journal of Clinical Psychiatry ·Jonathan Davidson, Anjana Bose, Qin Wang	26
15	A Double-Blind Comparison of Escitalopram and Paroxetine in the Long-Term Treatment of Generalized Anxiety Disorder 2005 ·Annals of Clinical Psychiatry ·Robert J. Bielski, Anjana Bose, (unknown)	80
16	Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials 2005 ·Journal of Affective Disorders ·Wayne K. Goodman, Anjana Bose, Qin Wang	83
17	Escitalopram Continuation Treatment Prevents Relapse of Depressive Episodes 2004 ·The Journal of Clinical Psychiatry ·Mark Hyman Rapaport, Anjana Bose, Hongjie Zheng	102
18	Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study 2004 ·Depression and Anxiety ·Jonathan Davidson, Anjana Bose, Andrew Korotzer, Hongjie Zheng	133
19	Naturalistic study of the early psychiatric use of citalopram in the United States 2002 ·Depression and Anxiety ·A. John Rush, Anjana Bose, William E. Heydorn	6
20	Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients 2002 ·The Journal of Clinical Psychiatry ·W. J. Burke, I. Gergel, Anjana Bose	277

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact